Immunogene therapy - Briana Bio-Tech

Drug Profile

Immunogene therapy - Briana Bio-Tech

Alternative Names: B7-2 gene therapy - Briana Bio-Tech

Latest Information Update: 28 May 2007

Price : $50

At a glance

  • Originator University of Alberta
  • Developer Briana Bio-Tech
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glioma; Malignant melanoma

Most Recent Events

  • 27 Nov 2000 No-Development-Reported for Glioma in Canada (Unknown route)
  • 27 Nov 2000 No-Development-Reported for Malignant melanoma in Canada (Unknown route)
  • 04 May 1998 Phase-I clinical trials for Glioma in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top